- Home
- NRC vs SCTX Comparison
NRC vs SCTX Comparison
Compare NRC & SCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRC | SCTX |
|---|---|---|
| Founded | 1981 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 483.3M | 536.5M |
| IPO Year | 1997 | 2026 |
Fundamental Metrics
Financial Performance| Metric | NRC | SCTX |
|---|---|---|
| Price | $20.63 | $30.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 102.4K | ★ 209.7K |
| Earning Date | 04-28-2026 | N/A |
| Dividend Yield | ★ 3.86% | N/A |
| EPS Growth | ★ 4707.69 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $119,686,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.81 | N/A |
| 52 Week Low | $11.01 | $17.31 |
| 52 Week High | $23.68 | $39.60 |
Technical Indicators
Market Signals| Indicator | NRC | SCTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.12 | 56.22 |
| Support Level | $17.82 | $19.09 |
| Resistance Level | $22.48 | $34.64 |
| Average True Range (ATR) | 0.88 | 4.80 |
| MACD | -0.09 | 0.00 |
| Stochastic Oscillator | 7.82 | 52.19 |
Price Performance
Historical ComparisonAbout NRC National Research Corporation (Delaware)
NRC Health operates as a humanized healthcare and support organization. Its platform includes Listen, Understand, and Improve. The group provides solutions for Patient, Consumer, Employee, and Market experiences. The group's commitment to Human Understanding helps healthcare systems get to know the patients, families, consumers, employees, and communities it on a human level.
About SCTX Scribe Therapeutics Inc. Common Stock
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.